

# Synthesis and evaluation of hydrogen peroxide sensitive tofacitinib prodrugs

Previtali, Viola; Keiding, Ulrik Bering; Olsen, Asger Hegelund; Peiró Cadahía, Jorge; Clausen, Anne Skovsbo; Kjaer, Andreas; Andresen, Thomas Lars; Hansen, Anders Elias; Clausen, Mads Hartvig

Published in: European Journal of Medicinal Chemistry Reports

Link to article, DOI: 10.1016/j.ejmcr.2021.100019

Publication date: 2022

Document Version Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

Previtali, V., Keiding, U. B., Olsen, A. H., Peiró Cadahía, J., Clausen, A. S., Kjaer, A., Andresen, T. L., Hansen, A. E., & Clausen, M. H. (2022). Synthesis and evaluation of hydrogen peroxide sensitive tofacitinib prodrugs. *European Journal of Medicinal Chemistry Reports*, *4*, Article 100019. https://doi.org/10.1016/j.ejmcr.2021.100019

## **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.

- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Contents lists available at ScienceDirect



European Journal of Medicinal Chemistry Reports

journal homepage: www.editorialmanager.com/ejmcr/default.aspx

# Synthesis and evaluation of hydrogen peroxide sensitive tofacitinib prodrugs



Viola Previtali<sup>a,b</sup>, Ulrik Bering Keiding<sup>a,b</sup>, Asger Hegelund Olsen<sup>a,b</sup>, Jorge Peiró Cadahía<sup>a,b</sup>, Anne Skovsbo Clausen<sup>c,d</sup>, Andreas Kjaer<sup>c,d</sup>, Thomas Lars Andresen<sup>a,e</sup>, Anders Elias Hansen<sup>a,e</sup>, Mads Hartvig Clausen<sup>a,b,\*</sup>

<sup>a</sup> Center for Nanomedicine & Theranostics, Technical University of Denmark, Denmark

<sup>b</sup> Department of Chemistry, Technical University of Denmark, Kemitorvet 207, 2800, Kgs. Lyngby, Denmark

<sup>c</sup> Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen, Denmark

<sup>d</sup> Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark

e Biotherapeutic Engineering and Drug Targeting, Department of Health Technology, Technical University of Denmark, Produktionstorvet, 2800, Kgs. Lyngby, Denmark

#### ARTICLE INFO

Keywords: Rheumatoid arthritis Inflammation Tofacitinib Prodrug Janus kinase inhibitor Reactive oxygen species

## ABSTRACT

Tofacitinib (CP-690,550), an approved Janus kinase (JAK) inhibitor, has been proven highly efficacious in treating rheumatoid arthritis (RA). Unfortunately, tofacitinib's clinical application has been limited by adverse side effects that arise from its pan-JAKs inhibition and ubiquitous biodistribution. In this study, we have examined whether a reactive oxygen species (ROS)-activated prodrug design could be applied to tofacitinib to potentially avoid its systemic JAK inhibition and thereby reduce its adverse effects. The prodrug strategy selected is based on ROS-labile 4-methylphenylboronic acid pro-moieties linked to the drugs via a carbamate linkage (prodrug 1) or a direct C–N bond (prodrug 2). Activation under pathophysiological concentrations of  $H_2O_2$  was investigated and conversion to desired tofacitinib assessed. The most promising prodrug candidate, prodrug 2, was selected in agreement with relevant *in vitro* physicochemical assay and *in silico* predicted ADME properties. Selected candidate prodrug 2 showed a remarkable potency window compared to tofacitinib in an *in vitro* kinase assay against JAK1 and JAK3 kinases. Importantly, prodrug 2 displayed a similar pharmacokinetic profile to tofacitinib after single dose *i.p.* administration to DBA/1 mice. This study supports the promising applications of ROS-sensitive tofacitinib prodrugs. Their further development and applicability would enhance tofacitinib's therapeutic efficacy, and may provide an opportunity for future development of safer tofacitinib dosing regimens.

## 1. Introduction

Tofacitinib (CP-690,550) is a JAK (Janus kinase) inhibitor approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA). It was the first drug targeting a specific protein kinase to be developed outside the field of cancer [1]. Tofacitinib has also been used successfully for psoriatic arthritis, ulcerative colitis, and, in the last year, in trials to test its effect in lowering the risk of death and respiratory failure among patients hospitalized with Covid-19 pneumomnia [2].

The success of tofacitinib stimulated the development of additional JAK inhibitors, which are either already approved (e.g. baricitinib, upadacitinib, and filgotinib) or undergoing clinical trials for others immune-mediated diseases beyond rheumatoid arthritis [3–5].

Tofacitinib is a pan-JAK kinase inhibitor that targets four members of the JAK family of protein tyrosine kinases, JAK1, JAK2, JAK3, and TYK2 [6], modulating the actions of about 25 cytokines and interferons [1]. Despite the indisputable advantages of using tofacitinib for patients who do not respond, or are intolerant to methotrexate [7],

https://doi.org/10.1016/j.ejmcr.2021.100019

Received 16 October 2021; Received in revised form 17 November 2021; Accepted 20 November 2021 Available online 24 November 2021

2772-4174/© 2021 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).

Abbreviations: ADME, absorption, distribution, metabolism, excretion; ATP, adenosine triphosphate; AUC, area under curve; DBA, dilute brown non-agouti; DIPEA, N,N-diisopropylethylamine; DMF, dimethylformamide; FDA, US Food and Drug Administration; i.p., intraperitoneal; JAK, Janus kinase; PAINS, pan-assay interference compounds; PBS, phosphate buffered saline; RA, rheumatoid arthritis; ROS, reactive oxygen species.

<sup>\*</sup> Corresponding author. Center for Nanomedicine & Theranostics, Technical University of Denmark, Kemitorvet 207, 2800 Kgs. Lyngby, Denmark.

E-mail address: mhc@kemi.dtu.dk (M.H. Clausen).

tofacitinib's multi-target activity is also responsible for its undesirable side effects, including infection, lipid levels alterations, and malignancies [8].

The long history of safety concerns is a serious impediment that affects JAK inhibitors other than tofacitinib, casting doubt on their long-term use for rheumatoid arthritis treatment [9]. In this perspective, newer and selective JAK inhibitors that narrow the spectrum of cytokine pathways involved are now under development, but, despite the hypothesis that improved JAK selectivity is possible and efficacious against inflammatory diseases, clinical approval is still pending [10].

Other than the development of JAK-selective inhibitors, one way of potentially reducing adverse effects is to avoid systemic JAK inhibition, given that tofacitinib's toxicity can in part be attributed to its ubiquitous biodistribution [11].

In this context, a number of reactive oxygen species (ROS)-sensitive functionalities have been identified for introducing disease-targeting properties into small molecule drugs – a prodrug strategy that offers a promising approach for increasing the selectivity and efficacy of treatments [12–14]. Applications of ROS sensitive prodrugs encompass many therapeutic areas, among the latest we find: gemcitabine derivatives for the selective treatment of pancreatic ductal adenocarcinoma [15], Keap1-Nrf2 targeting prodrugs for selective activation in inflammatory conditions [16], a selective small molecule ATF6 activator for protection of tissue damage following ischemia/reperfusion [17], and first in class tyrosine kinase inhibitor crizotinib prodrug [1].

Examples of ROS sensitive prodrugs using JAK inhibitors and application in RA was recently presented by Bao et al. with their report of an  $H_2O_2$ -inducible JAK3 covalent inhibitor [18]. Moreover, in 2018 Wei et al. reported the development of a macromolecular prodrug of tofacitinib with modified pharmacokinetics and biodistribution properties, favoring accumulation in arthritic joints and reducing systemic JAK inhibition [19].

Inspired by the ROS-activated prodrug strategy and following our previous work [20,21], we designed and synthesized prodrugs 1 and 2. The compounds both have a ROS-labile 4-methylphenylboronic acid promoiety linked to the tofacitinib pyrrolopyrimidine via a carbamate

linkage (1) or a direct C–N bond (2, Fig. 1). Triggered by ROS (e.g. hydrogen peroxide,  $H_2O_2$ ) the B–C bond undergoes oxidation via coordination of  $H_2O_2$  to the boron atom followed by aryl bond migration to form an intermediate borate that rapidly hydrolyses in water to generate a phenol and boric acid (Fig. 1). To assess the ability of prodrugs 1 and 2 to release tofacitinib, we evaluated their activation profile. Chemical stability was also investigated and compared with negative control 3 that is lacking the boronic acid. Furthermore, physicochemical properties and *in silico* descriptors to predict ADME parameters and drug-likeness of the prodrugs were evaluated. Additionally, *in vitro* JAK1/JAK3 kinase inhibition of the prodrugs was assessed, and the *in vivo* pharmacokinetics evaluated to compare them to the parent drug tofacitinib.

### 2. Results and discussion

### 2.1. Synthesis of prodrugs

Tofacitinib was purchased as its citrate salt and used as a starting point for synthesis of prodrugs **1**, **2**, and negative control **3**. Pinacolate **4** was converted into the corresponding chloroformate **5** with phosgene, as previously described [20]. Coupling between tofacitinib citrate and **5** afforded pinacol-intermediate **6**, which underwent oxidative cleavage with sodium periodate to deliver prodrug **1** in a good yield. Similarly, coupling between tofacitinib citrate and benzyl chloroformate **7** afforded compound **3**, used as a negative control due its lacking of the ROS-liable boron-containing moiety. Alkylation of tofacitinb citrate with 4-(bromomethyl)phenyl)boronic acid **8** afforded the second prodrug, **2** (Scheme 1).

### 2.2. Activation of prodrugs

 $H_2O_2$  is the most stable ROS and, under pathological inflammatory conditions, its extracellular concentration can be as high as 1.0 mM [12]. We therefore moved to the investigation of the effect of  $H_2O_2$  on prodrug activation. We evaluated the release of prodrug 1 and 2 using  $H_2O_2$  at different concentrations (0.25 mM and 1 mM) for up to 24 h and at 37 °C. As shown in Fig. 2(A), prodrug 1 was completely converted to tofacitinib



Fig. 1. Structures of tofacitinib, proposed prodrugs 1 and 2, negative control 3, and their H<sub>2</sub>O<sub>2</sub>-mediated release mechanism.

European Journal of Medicinal Chemistry Reports 4 (2022) 100019



Scheme 1. Synthesis of tofacitinib prodrugs 1 and 2, and negative control 3<sup>a</sup>. <sup>a</sup>Reagents and conditions: (a) phosgene (20% in toluene), dioxane, rt, 16 h, 100% [20]; (b) 5, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 4 h, 20%; (c) acetone, NaIO<sub>4</sub>, NH<sub>4</sub>OAc (aq., 500 mM), rt, 2 h, 70%; (d) CbzCl 7, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 16 h, 54%; (e) 4-(bromomethyl)phenyl)boronic acid **8**, DIPEA, DMF, 55 °C, 2 h, 27%.



Fig. 2. Activation profile of prodrugs 1 (A, left) and 2 (B, right).

after only 1 h of incubation with  $H_2O_2$  at 1 mM, while using  $H_2O_2$  at 0.25 mM, complete conversion was achieved at 24 h. Comparatively, complete conversion of prodrug **2** was achieved after 8 h of incubation with  $H_2O_2$  at 1 mM. As expected, the release of tofaticinib was significantly slower due to the metastable intermediate phenol, and was only achieved after  $\geq$ 24 h Fig. 2(B). This behavior is in line with previous observations for prodrugs of MTX and AMT having a carbamate and C–N linker,

Table 1
Chemical stability and permeability of tofacitinib free base, 1, and 3.

	Tofacitinib (free base)		
PBS (t <sub>1/2</sub> , h)	-	>24	_
SGF	-	$\textbf{23.7} \pm \textbf{3.1}$	>24
SIF	-	$\textbf{0.7} \pm \textbf{0.1}$	< 1
PAMPA (Pe, $\times 10^{-6}$ cm/s)	$\textbf{0.82}\pm\textbf{0.11}$	BQL	-

SGF: simulated gastric fluid; SIF: simulated intestinal fluid; PAMPA: parallel artificial membrane permeability assay.

respectively [20]. Importantly, the AMT prodrug was active in a CIA mouse model of arthritis, demonstrating that longer release times does not hamper activity of the parent drug upon release.

# 2.3. Chemical stability and physicochemical properties

We then moved to the evaluation of the chemical stability and permeability, see Table 1. Predicted adsorption, distribution, metabolism, excretion (ADME) parameters of prodrug 1, prodrug 2, and the parent drug tofacitinib were calculated using the web tool SwissADME [22], and can be found in supporting information.

The carbamate linker common to prodrug **1** and negative control **3** was stable in PBS and simulated gastric fluid (SGF) with half-lives above 24 h. In simulated intestinal fluid (SIF), the half-life for prodrug **1** was found to be lower than 1 h, indicating a chemical liability traceable to the carbamate linker rather than the *C*–B bond, since the half-life of negative control **3** was also highly reduced (<1h, Table 1).

Predicted solubility for prodrugs 1 and 2 was 56.8  $\mu$ g/mL and 87.0  $\mu$ g/mL respectively, against a higher solubility of 559  $\mu$ g/mL for tofacitinib (Table S1).

Overall, despite the good ROS-activation profile and no PAINS alerts, prodrug **1** proved to be unstable in SIF and has low solubility that prevented further investigation. Instead, we decided to investigate prodrug **2** further in an *in vitro* JAK inhibition assay and to evaluate its *in vivo* pharmacokinetics compared to tofacitinib.

## 2.4. In vitro kinase assay

Tofacitinib is a reversible, competitive inhibitor that binds to the adenosine triphosphate (ATP) binding site and, as a result, inhibits the phosphorylation and activation of the JAK family of kinases. This prevents the phosphorylation and activation of STATs, and thus the activation of gene transcription and the following cytokine production and modulation of the immune response.

The original report in which it was described [23] provided evidence that tofacitinib inhibited JAK3 with an IC<sub>50</sub> value of 1 nM while inhibiting JAK2 and JAK1 at higher IC<sub>50</sub> values of 20 and 112 nM, respectively. Herein, we have reported an in vitro kinase assay to assess prodrug 2 ability to inhibit JAK1 and JAK3, and to compare it with tofacitinib's potency (Table 2, Fig. 3). Both prodrug 2 and tofacitinib were tested against the kinase of interest in 9-points concentrations, ranging from 1 nM to 10  $\mu$ M. The resulted estimated IC<sub>50</sub> values for tofacitinib (2.8 nM) correlated well with the reported value against JAK3, while a 30-fold discrepancy was observed for JAK1 (3.3 nM compared to 112 nM). This difference can arise from different experiment condition, especially for different ATP concentration used. Importantly, the difference from tofacitinib and prodrug 2 was remarkable with a calculated IC50 against JAK1 and JAK3 of 414 and 408 nM, respectively. This relatively strong effect of prodrug 2 against JAK1 and JAK3 could be explained by possible partial hydrolysis of the prodrug in the kinase assay buffer used or by unspecific interactions established by the aryl-boronic moiety. Despite the importance of tofacitinib pyrrolopyrimidine's hydrogen for establishing an hydrogen bond with E903 at the ATP binding site [24], other derivatives have shown their selectivity towards JAK3 through specific lipophilic interactions [8]. Nevertheless, the close to 200-fold difference indicates that prodrug 2 could have only minimal activity against the kinase of interest, mimicking tofacitinib pharmacodynamics only when freed from its aryl-boronic acid prodrug moiety.

### 2.5. Pharmacokinetics

The *in vivo* pharmacokinetic profiles for tofacitinib and prodrug **2** were compared. Tofacitinib citrate (80.8 mg/kg, equimolar to 50 mg/ kg for tofacitinib free base) and equimolar doses of prodrug **2** were administered *i.p.* to DBA/1 mice [25]. Blood was collected from the treated mice at 0.25, 1, 7, and 24 h, and analyzed by LC-MS/MS. Even though tofacitinib showed an overall higher exposure level than prodrug **2**, good level of  $C_{max}$  (36.0  $\mu$ M) and AUC<sub>calc</sub> (1646 min\*mg/L)

Table 2 Estimated IC  $_{50}$  values (ATP concentrations: 45  $\mu M$  for JAK1 and 10  $\mu M$  for JAK3).

Compound	Kinase	IC <sub>50</sub> (nM)		
Tofaticinib Citrate	JAK1(h)	$3.3 \pm 1.1 \ (112) \ [23]$		
Tofaticinib Citrate	JAK3(h)	$2.8 \pm 1.1$ (1) [23]		
prodrug 2	JAK1(h)	$414.1 \pm 1.1$		
prodrug 2	JAK3(h)	$\textbf{408.8} \pm \textbf{1.1}$		

(h): human; measurements were obtained in duplicates; tofacitinib literature values are reported in brackets.

were also found for prodrug **2** (Table 3). Tofacitinib's half-life agreed to literature's reported values (<1 h) [26,27] and prodrug **2** showed similar value. Calculated clearance (CL) was found similar between tofacitinib and prodrug **2** (low to moderate, 33.0 and 43.4 mL/min/kg, respectively). Remarkably, prodrug **2** showed stability in mouse plasma over 24 h, releasing less than 2% of tofacitinib over 24 h (data not shown).

## 3. Conclusions

In this report, we have described the synthesis of new arylboronic acid-based hydrogen peroxide-sensitive tofacitinib prodrugs for putative RA inflammatory tissues site-selective delivery, with the aim of reducing side effects in tofacitinib therapy. Between the two prodrugs synthesized, prodrug 2 showed more favorable physicochemical properties and a slower activation profile under pathophysiological concentrations of  $H_2O_2$ . Prodrug 2 achieved complete conversion to the corresponding drug tofacitinib in the reasonable timeframe of 24 h (at a H<sub>2</sub>O<sub>2</sub> concentration of 1 mM). Prodrug 2 activity against kinase of interest JAK1 and JAK3 was assessed using an in vitro kinase assay and proved to be around 150-fold lower than that of tofacitinib, indicating an attractive activity window, and validating the proof-of-concept prodrug strategy. Importantly, the pharmacokinetic data demonstrate that a single dose of prodrug 2 at 71.4 mg/kg achieved an exposure in plasma similar to tofacitinib citrate (80.8 mg/kg) for up to 7 h, exhibiting favorable ADME properties. These findings could open up future work on additional in vivo studies to establish drug/prodrug concentration in RA rodent models and, ultimately, antiarthritic efficacy to hopefully advance these promising prodrugs towards clinical evaluation.

## 4. Experimental

## 4.1. General

Commercially available reagents were used without further purification and all solvents were of HPLC quality. Reactions were monitored by thin layer chromatography (TLC) and/or reversed-phase ultra-performance liquid chromatography mass spectrometry (RP-UPLC-MS). Analytical TLC was conducted on Merck aluminum sheets covered with silica (C60) and visualized under UV-light. Analytical RP-UPLCMS (ESI) analysis was performed on a S2 Waters AQUITY RP-UPLC system equipped with a diode array detector using an Thermo Accucore C18 column (d 2.6  $\mu$ m, 2.1  $\times$  50 mm; column temp: 50 °C; flow: 1.0 mL/min). Eluents A (10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O) and B (10 mM NH<sub>4</sub>OAc in MeCN) were used in a linear gradient (5% B to 100% B) in 2.4 min and then held for 0.1 min at 100% B (total run time: 2.6 min). The LC system was coupled to a SQD mass spectrometer. All compounds were characterized by <sup>1</sup>H NMR, <sup>13</sup>C NMR, IR, HRMS (ESI), melting point, and specific rotation. Flash column chromatography was performed using Merck Geduran® Si 60 (40-63 µm) silica gel. Purification of reactions by preparative RP-HPLC was performed on a Waters Alliance reverse-phase HPLC system consisting of a Waters 2545 Binary Gradient Module equipped with either an xBridge BEH C18 OBD Prep Column (130 Å, 5  $\mu m,\,30\,\times\,150$  mm) or an xBridge Peptide BEH C18 OBD Prep Column (130 Å, 5  $\mu$ m, 19 mm  $\times$  100 mm) both operating at 20 °C and a flow rate of 20 mL/min, a Waters. Photodiode Array Detector (detecting at 210-600 nm), a Waters UV Fraction Manager, and a Waters 2767 Sample Manager. Elution was carried out in a reversed-phase gradient fashion combining A1 (0.1% HCO<sub>2</sub>H in milli-Q water) and B1 (0.1% HCO<sub>2</sub>H in CH<sub>3</sub>CN): 5% B to 70% B in 10 min, hold for 3.5 min, then 70% B to 100% B in 1.5 min, and hold 3 min. Total run time: 20 min. NMR data were acquired at 298 K using a Bruker Ascend spectrometer (operating at 400



Fig. 3. IC<sub>50</sub> dose-response curves of tofacitinib citrate against JAK1 and JAK3 (left), and of prodrug 2 (right).

Table 3 Pharmacokinetics parameters of tofacitinib and prodrug 2 in healthy DBA/1 mice.

	tofacitinib (citrate)	prodrug 2		
Dose	80.8 mg/kg ( <i>i.p.</i> )	71.4 mg/kg (i.p.)		
C <sub>max</sub> (obs)	33.4 mg/L (66.2 μM)	16.1 mg/L (36.0 μM)		
T <sub>max</sub> (obs)	15 min	15 min		
AUC <sub>0-last</sub> (calc)	2445 min*mg/L	1646 min*mg/L		
t <sub>1/2</sub> (calc)	<1 h	<1 h		
CL (calc)	33.0 mL/min/kg	43.4 mL/min/kg		

MHz for proton and 101 MHz for carbon). The chemical shifts ( $\delta$ ) are reported in parts per million (ppm) and the coupling constants (J) in Hz. For spectra recorded in DMSO- $d_6$ , chemical shifts are reported relative to the signal for DMSO- $d_6$  ( $\delta$  2.50 ppm for <sup>1</sup>H NMR and  $\delta$  39.52 ppm for <sup>13</sup>C NMR). NMR data was analyzed using MestReNova (v11.0.0-17,609) by Mestrelab Research S.L. IR analysis was performed on a Bruker Alpha FT-IR spectrometer. Melting points were obtained using a Stuart SMP30 melting point apparatus and are uncorrected. Analytical LC-HRMS (ESI) analysis was performed on an Agilent 1100 RP-LC system equipped with a diode array detector using a Phenomenex Luna C18 column (d =  $3 \mu m$ ,  $2.1 \times 50$  mm; column temp: 40 °C; flow: 0.4 mL/min). Eluents A (0.1% HCO<sub>2</sub>H in H<sub>2</sub>O) and B (0.1% HCO<sub>2</sub>H in MeCN) were used in a linear gradient (20% B to 100% B) in a total run time of 15 min. The LC system was coupled to a Micromass LCT orthogonal time-of-flight mass spectrometer equipped with a Lock Mass probe operating in positive electrospray mode. Optical rotations were measured on a PerkinElmer Model

341 Polarimeter (cuvette 1.0 mL, 100 mm) using a sodium source lamp (589 nm, 20  $^\circ \rm C).$ 

### 4.2. Synthesis

# 4.2.1. 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl 4-(((3R,4R) -1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidine-7-carboxylate (6)

To a suspension of tofacitinib citrate (1.78 mmol, 1 equiv.) in CH<sub>2</sub>Cl<sub>2</sub> (17 mL) was added DIPEA (10.68 mmol, 6 equiv.). After 30 minutes of stirring, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl carbonochloridate (5) (2.14 mmol, 1.2 equiv.) in CH<sub>2</sub>Cl<sub>2</sub> (6 mL) was added and the reaction cooled to 0 °C. After stirring for 4 h at 0 °C, H<sub>2</sub>O was added to quench excess reagent and the crude mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and dried in vacuo. The residue was purified by flash chromatography (heptane:EtOAc, 20:80 -> 0:100) to afford the title compound as a white solid (208 mg, 20%). <sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 8.34–8.32 (m, 1H), 7.71 (d, J = 7.7 Hz, 2H), 7.57–7.57 (m, 3H), 6.89–6.87 (m, 1H), 5.50 (s, 2H), 4.85 (bs, 1H), 4.17-3.91 (m, 3H), 3.84-3.63 (m, 2H), 3.41-3.40 (m, 1H), 3.26 (s, 3H), 2.41-2.33 (m, 1H), 1.87-1.67 (m, 1H), 1.61-1.53 (m, 1H), 1.29 (s, 12H), 1.00 (d, J = 7.1 Hz, 3H). <sup>13</sup>C-NMR (101 MHz, DMSO- $d_6$ ):  $\delta$ 161.60, 161.49, 157.01, 152.53, 152.14, 148.99, 138.70, 134.59, 127.05, 121.70, 116.21, 106.63, 104.51, 83.71, 68.21, 53.08, 42.40, 41.59, 34.43, 30.89, 30.69, 24.92, 24.65, 13.70. HRMS (ESI) m/z: calcd for C<sub>30</sub>H<sub>37</sub>BN<sub>6</sub>O<sub>5</sub> [M+H]<sup>+</sup> 573.2918, found 573.2913. **IR** (neat, cm<sup>-1</sup>): 2976.33, 2930.71, 1758.90, 1739.88, 1658.99, 1567.48, 1532.84, 1357.51, 1294.93, 1271.47, 1166.11, 1140.81, 1087.16, 1013.54, 856.84, 720.03, 657.11. m.p.: 123–125 °C.  $[\alpha]_D^{20}$  + 13.1° (c 0.38, CHCl<sub>3</sub>).

# 4.2.2. (4-(((4-(((3R,4R)-1-(2-Cyanoacetyl)-4-methylpiperidin-3-yl) (methyl)amino)-7H-pyrrolo[2,3-d]pyrimidine-7-carbonyl)oxy)methyl) phenyl)boronic acid (1)

To a solution of pinacol precursor 6 (0.20 mmol, 1 equiv.) in acetone (2.5 mL), a 500 mM aq. solution of NH<sub>4</sub>OAc in H<sub>2</sub>O (1.20 mmol, 6 equiv.), and NaIO<sub>4</sub> (1.20 mmol, 6 equiv.) were added. After 2 hours stirring at room temperature, the precipitate was filtered off and the mixture evaporated in vacuo. The residue was purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>:2-propanol, 90:10 -> 80:20) to afford the title compound as a white solid (70 mg, 70%). <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ ):  $\delta$ 8.33–8.32 (m, 1H), 8.08 (s, 2H), 7.82 (d, J = 7.9 Hz, 2H), 7.58 (d, J = 4.2 Hz, 1H), 7.50 (d, J = 7.9 Hz, 2H), 6.89–6.86 (m, 1H), 5.48 (s, 2H), 4.85 (bs, 1H), 4.17-3.91 (m, 3H), 3.84-3.63 (m, 2H), 3.46-3.40 (m, 1H), 3.26 (s, 3H), 2.41-2.34 (m, 1H), 1.86-1.68 (m, 1H), 1.60-1.53 (m, 1H), 1.04–0.99 (m, 3H). <sup>13</sup>C-NMR (101 MHz, DMSO-*d*<sub>6</sub>): δ 161.61, 161.50, 157.02, 152.51, 152.15, 149.01, 137.08, 134.27, 126.74, 121.76, 116.23, 106.62, 104.52, 68.43, 53.10, 42.41, 41.60, 34.43, 30.91, 30.66, 24.93, 13.71. HRMS (ESI) m/z: calcd for C<sub>24</sub>H<sub>27</sub>BN<sub>6</sub>O<sub>5</sub> [M+H]<sup>+</sup> 491.2136, found 491,2133. **IR** (neat, cm<sup>-1</sup>): 2966.60, 2927.43, 1754.55, 1650.32, 1569.49, 1533.98, 1492.50, 1454.01, 1433.69, 1411.70, 1379.66, 1332.74, 1294.77, 1276.06, 1166.98, 1125.46, 1013.60, 978.6, 950.16, 719.37. m.p.: 190 °C (decomp).  $[\alpha]_D^{20}$  + 8.6° (c 0.49, DMSO).

# 4.2.3. (4-(((4-(((3R,4R)-1-(2-Cyanoacetyl)-4-methylpiperidin-3-yl) (methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)phenyl)boronic acid (2)

To a solution of tofacitinib free base (1.13 mmol, 1 equiv.) in DMF (4.5 mL), DIPEA (2.26 mmol, 2 equiv.) and (4-(bromomethyl)phenyl) boronic acid 8 (1.36 mmol, 1.2 equiv.) were added. After 2 h stirring at 55 °C, the mixture was evaporated *in vacuo* and the mixture purified with reverse phase preparative HPLC to afford the title compound as a white solid (138 mg, 27%). <sup>1</sup>H-NMR (400 MHz, DMSO-d<sub>6</sub>): δ 8.62-8.57 (m, 1H), 8.22 (s, 2H), 7.72 (d, J = 7.7 Hz, 2H), 7.38-7.27 (m, 3H), 6.71 (s, 1H), 5.56 (s, 2H), 4.95 (bs, 1H), 4.17-3.95 (m, 3H), 3.82-3.65 (m, 2H), 3.40-3.35 (m, 4H), 2.39 (s, 1H), 1.83-1.71 (m, 1H), 1.61-1.58 (m, 1H), 1.02–1.01 (m, 3H). <sup>13</sup>C-NMR (101 MHz, DMSO- $d_6$ ):  $\delta$  163.81, 161.58, 155.96, 142.44, 137.55, 134.31, 133.58, 126.85, 126.76, 116.22, 104.31, 104.10, 54.90, 51.57, 42.38, 41.48, 34.84, 31.21, 30.84, 24.95, 13.65. HRMS (ESI) *m/z*: calcd for C<sub>23</sub>H<sub>27</sub>BN<sub>6</sub>O<sub>3</sub> [M+H]<sup>+</sup> 447.2238, found 447.2219. IR (neat, cm<sup>-1</sup>): 3306.43, 3080.63, 3051.90, 2930.64, 2798.93, 1650.93, 1615.02, 1575.50, 1540.22, 1514.45, 1454.02, 1409.77, 1372.31, 1337.62, 1250.77, 1218.64, 1182.95, 1122.99, 1016.93, 732.45. **m.p.:** 219 °C (decomp.).  $[\alpha]_D^{20}$  + 5.8° (*c* 0.36, DMSO).

# 4.2.4. Benzyl 4-(((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3yl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidine-7-carboxylate (3)

To a suspension of tofacitinib citrate (0.59 mmol, 1 equiv.) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added DIPEA (3.57 mmol, 6 equiv.). After 15 minutes of stirring, CbzCl **7** (0.71 mmol, 1.2 equiv.) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added and the reaction cooled to 0 °C. After stirring for 1 h at 0 °C, the reaction was left stirring overnight at room temperature. H<sub>2</sub>O was then added to quench excess reagent and the crude mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and dried *in vacuo*. The residue was purified by flash chromatography (heptane:EtOAc, 20:80 -> 0:100) to afford the title compound as a pink solid (144 mg, 54%). <sup>1</sup>**H**-**NMR** (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.33–8.32 (m, 1H), 7.57–7.54 (m, 3H), 7.44–7.34 (m, 3H), 6.88–6.84 (m, 1H), 5.48 (s, 2H), 4.84 (bs, 1H), 4.19–3.91 (m, 3H), 3.85–3.62 (m, 2H), 3.42–3.40 (m, 1H), 3.26 (s, 3H), 2.40–2.33 (m, 1H), 1.85–1.66 (m, 1H), 1.60–1.56 (m, 1H), 1.00 (d, *J* =

7.1 Hz, 3H). <sup>13</sup>C-NMR (101 MHz, DMSO- $d_6$ ):  $\delta$  161.61, 161.49, 157.01, 152.51, 152.14, 148.99, 135.40, 128.53, 128.28, 127.92, 121.73, 116.22, 106.56, 104.51, 68.43, 53.07, 42.41, 41.60, 34.43, 30.89, 30.66, 30.00, 24.92, 13.71. HRMS (ESI) m/z: calcd for C<sub>24</sub>H<sub>26</sub>N<sub>6</sub>O<sub>3</sub> [M+H]<sup>+</sup> 447.2066, found 447.2057. IR (neat, cm<sup>-1</sup>): 2933.93, 1732.86, 1653.01, 1566.97, 1532.01, 1453.83, 1294.91, 1166.28, 1014.14, 719.82. m.p.: 75–76 °C.  $[\alpha]_D^{20}$  + 19.5° (*c* 0.37, CHCl<sub>3</sub>).

# 4.3. Chemical stability and PAMPA assay

# 4.3.1. Activation with hydrogen peroxide $(H_2O_2)$

Prodrug 1: 50  $\mu$ L of a 1 mM solution of prodrug 1 in DMSO was added to PBS (375  $\mu$ L) together with 50  $\mu$ L of a 1 mM DMSO solution of diclofenac. For activation, 25  $\mu$ L of 20 mM or 5 mM H<sub>2</sub>O<sub>2</sub> solution in PBS were added. The solution was then mixed and placed in an Eppendorf Thermomixer (1000 rpm, 37 °C). Aliquots of 50  $\mu$ L were taken after 0 min, 15 min, 30 min, 1 h, 2 h, 4 h and 24 h. Analysis was performed as detailed in the analysis section below.

Prodrug 2: 50  $\mu L$  of a 20 mM solution of prodrug 2 in DMSO was diluted with 425  $\mu L$  of water and 25  $\mu L$  of 20 mM  $H_2O_2$  solution was added. 200  $\mu L$  of the solution was transferred to a vial and immediately to the UPHLC-MS instrument for analysis. Analysis by UHPLC-MS/MS was performed at 0 min, 15 min, 30 min, 1 h, 2 h, 4, 8 h, and 24 h. The data was normalized to the 0 minutes data for prodrug 2 and to the 24 h data for tofaticinib.

# 4.3.2. Stability in PBS

Prodrug (2  $\mu$ L, 10 mM in DMSO) was added to a solution of prewarmed PBS (1998  $\mu$ L) to obtain a final prodrug concentration of 10  $\mu$ M (0.1% DMSO). 500  $\mu$ L of the mixture was then placed in an Eppendorf Thermomixer C (1.5 mL, 1000 rpm). Aliquots of 50  $\mu$ L were taken after 0, 2, 4, 6 and 24 h and quenched with 50  $\mu$ L of ice-cold MeOH containing an internal standard (diclofenac 10  $\mu$ M, 0.1% DMSO). Analysis was performed as detailed in the analysis section below.

# 4.3.3. Stability in simulated gastric fluid (SGF) [20]

Sodium chloride (0.20 g), concentrated HCl (0.70 mL), and pepsin (Sigma, P-7000, 0.32 g) were added to deionized water (99.30 mL) to obtain a simulated gastric fluid (SGF) solution with a final volume of 100 mL. A solution of prodrug (10  $\mu$ L, 10 mM in DMSO) was added to a solution of SGF (990  $\mu$ L) and the mixture was incubated at 37 °C in an Eppendorf Thermomixer C (1.5 mL, 1000 rpm). Aliquots of 90  $\mu$ L were taken after 0, 1, 2, 4, and 24 h. To the aliquots was added 10  $\mu$ L of diclofenac (1 mM in DMSO) as an internal standard. Analysis was performed as detailed in the analysis section below.

## 4.3.4. Stability in simulated intestinal fluid (SIF) [20]

Monobasic potassium phosphate ( $KH_2PO_4$ , 0.68 g), sodium hydroxide (38 mL, 0.1 M, aq.), and pancreatin (Sigma, P-1625, 1.0 g) were added to deionized water (62 mL) to obtain the simulated

intestinal fluid (SIF) with a final volume of 100 mL. Using a pH-meter the pH of the solution was adjusted to 7.5 by the addition of sodium hydroxide (1 M, aq.). A solution of prodrug (10  $\mu$ L, 10 mM in DMSO) was added to a solution of SIF (990  $\mu$ L) and the mixture was incubated at 37 °C in an Eppendorf Thermomixer C (1.5 mL, 1000 rpm). Aliquots of 180  $\mu$ L were taken after 0, 1, 2, 4, and 24 h. The aliquots were transferred to an Eppendorf and centrifuged. Samples of 90  $\mu$ L of the supernatant was taken and diclofenac (10  $\mu$ L, 1 mM in DMSO) as an internal standard. Analysis was performed as detailed in the analysis section below.

# 4.3.5. Analysis

Samples were collected at the desired time points and then analyzed with RP-UPLC-MS ( $\lambda = 306$  nm). The % remaining compound was calculated using diclofenac as an internal standard and using the following equations. All experiments were done in at least three replicates.

ratio = 
$$\frac{AUC \text{ prodrug}}{AUC \text{ diclofenac}}$$

%remaining =  $\frac{\text{ratio at time point}}{\text{ratio at t} = 0}$ \*100

## 4.4. PAMPA assay

The PAMPA assay was performed using Corning® BioCoat™ Precoated PAMPA Plate System (Product number: 353,015) following a previously reported procedure [28,29]. Compound solutions were prepared by diluting 20  $\mu L$  of 20 mM stock solutions (DMSO) with 1980 µL of PBS. Caffeine was used as positive control. To the donor well was added 300  $\mu$ L/well of the 200  $\mu$ M test compound solution. To the acceptor well was added 200 µL/well of PBS. The acceptor plate was then slowly placed on top of the donor plate and incubated at room temperature for 5 h with no agitation. Samples of 150 µL from both the donor and the corresponding acceptor well were analyzed using RP-UPLC-MS ( $\lambda = 306$  nm) and concentration extrapolated with previously obtained calibration curves. The results were calculated as the average of at least three replicates. The permeability coefficients (Pe, cm/s) of the examined compounds were calculated using the following formula provided by the PAMPA Plate System manufacturer [30].

$$Pe = \left[ -\ln(1 - C_A / C_{eq}) \right] / \left[ A * (1 / V_D + 1 / V_A) * t \right]$$

where  $C_A$  is the compound concentration in the acceptor well after 5 hours;  $C_D$  is the compound concentration in the donor well after 5 hours;  $V_A$  is the volume in acceptor well (200 µL);  $V_D$  is the volume in the donor well (300 µL), t is the incubation time (s); and A is the filter area (0.3 cm<sup>2</sup>).  $C_{eq}$  is calculated using the equation below:

$$C_{eq} = [(C_D * V_D) + (C_A * V_A)] / (V_D + V_A)$$

## 4.5. In vitro kinase assay

Prodrug **2** and tofacitinb were assessed for binding at JAK1 and JAK3 protein kinases using a direct filter-binding radiometric kinase activity assay (KinaseProfiler<sup>TM</sup> - Eurofins). 9-point IC<sub>50</sub> curves were provided ranging from 1 nM to 10  $\mu$ M and using ATP concentrations of 45  $\mu$ M for JAK1 and 10  $\mu$ M for JAK3. IC<sub>50</sub> were calculated using GraphPrism and

log(inhibitor) vs. normalized response as non linear regression (curve fit).

## 4.6. In vivo pharmacokinetic

## 4.6.1. Mice

Six-week-old, female DBA/1JRj mice were purchased (Janvier, Le Genest-Saint-Isle, France) and housed in groups of 8 mice in individually ventilated cages under standardized lighting conditions (12 h light period) and fed pathogen-free food and water ad libitum. Mice were acclimatized for one week prior to the experiment. The animal experiment had been approved by The Animal Experiments Inspectorate in Denmark under the license number 2016-15-0201-00920, approved on 5 July 2016.

# 4.7. Single dose tofacitinib/prodrug 2 intervention and sampling

Mice were randomly divided into two groups (n = 8/group): group I (**tofacitinib**, 80.8 mg/kg, *i.p.*) and group II (prodrug **2**, 71.4 mg/kg, *i.p.*). Mice were treated with a single dose of **tofacitinib**/prodrug **2** and blood was collected from vena sublingualis at 0.25, 1, 7, and 24 h after administration. Both treatments were equimolar to 50 mg/kg for tofacitinib free base. The samples were stored at -80 °C until analysis by LC-MS/MS.

## 4.7.1. Sample preparation for UHPLC-MS/MS

40  $\mu$ L of whole blood was transferred to an Eppendorf tube and 160  $\mu$ L of ultrapure water was added followed by 200  $\mu$ L of methanol and 600  $\mu$ L of acetonitrile. The samples were mixed (10 s, 1500 rpm) using a benchtop vortex mixer and macromolecules allowed to precipitate for 10 minutes and room temperature. The precipitate was pelleted by centrifugation (10,000 g, 10 minutes, 4 °C) and 500  $\mu$ L of supernatant transferred to a clean eppendorf tube and concentrated using a SpeedVac. The samples were redissolved in 100  $\mu$ L of ultrapure water and analyzed using UHPLC-MS/MS. This method was adapted from work by Sørensen, L. K. and co-workers [31].

## 4.7.2. UHPLC-MS/MS analysis

The samples were analyzed using a Shimadzu LCMS-8045 LCMS equipped with a Phenomex C18 column (100  $\times$  2.1 mm, 2.6  $\mu$ m) kept at 40 °C. Mobile phase A was water with 0.1% formic acid and mobile phase B was acetonitrile with 0.1% formic acid. Flow rate: 0.5 mL/min. Gradient: Isocratic 10% B minute 0–0.5, linear from 10% to 60% B minute 0.5–3, linear from 60% to 100% B minute 3–3.50, isocratic 100% B minute 3.50–4, linear from 100% B to 10% B minute 4–4.50, isocratic 10% B minute 4.50–6. Injection: 5  $\mu$ L. For analysis of blood samples an external standard series was used to obtain semi-quantitative results. For MS-specifications refer to table below.

Quantification	Target	Mode	Precursor m/z	Product m/z	rt	Q1 Bias (V)	Q3 Bias (V)	CE (V)
$[M + H]^+$ $[M + H]^+$	Tofaticinib Prodrug 2	++++	313,20 447,20	149,25 283,20	1.742 2.670	-21 -16	-28 -14	-30 -27
Qualifying $[M \perp H]^+$	Tofaticinih	т	313 20	173 20	1 742	_21	_17	_37
$[M + H]^+$	Tofaticinib	+	313,20	98.20	1.742	-21	-18	-32
$[M + H]^{+}$	Prodrug 2	+	447,20	135,15	2.670	-16	-24	-33
$[M + H]^+$	Prodrug 2	+	447,20	117,10	2.670	-22	-21	-55

## 5. Chemical compounds studied in this article

Tofacitinib (PubChem CID: 9926791).

## Acknowledgments

We are grateful for financial support from the Independent Research Fund Denmark (grant no. 7017–00026) and the Technical University of Denmark (PoC funding). Graphical abstract image was created with BioRender.com.

# Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ejmcr.2021.100019.

## References

- P. Cohen, D. Cross, P.A. Jänne, Kinase drug discovery 20 years after imatinib: progress and future directions, Nat. Rev. Drug Discov. (2021).
- [2] P.O. Guimarães, D. Quirk, R.H. Furtado, L.N. Maia, J.F. Saraiva, M.O. Antunes, R. Kalil Filho, V.M. Junior, A.M. Soeiro, A.P. Tognon, V.C. Veiga, P.A. Martins, D.D.F. Moia, B.S. Sampaio, S.R.L. Assis, R.V.P. Soares, L.P.A. Piano, K. Castilho, R.G.R.A.P. Momesso, F. Monfardini, H.P. Guimarães, D. Ponce de Leon, M. Dulcine, M.R.T. Pinheiro, L.M. Gunay, J.J. Deuring, L.V. Rizzo, T. Koncz, O. Berwanger, Tofacitinib in patients hospitalized with covid-19 pneumonia, N. Engl. J. Med. (2021).
- [3] G.E. Fragoulis, I.B. McInnes, S. Siebert, JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis, Rheumatology 58 (Suppl 1) (2019) i43–i54.
- [4] R. Harrington, S.A. Al Nokhatha, R. Conway, JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data, J. Inflamm. Res. 13 (2020) 519–531.
- [5] J. Angelini, R. Talotta, R. Roncato, G. Fornasier, G. Barbiero, L. Dal Cin, S. Brancati, F. Scaglione, JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future, Biomolecules 10 (7) (2020).
- [6] J.A. Hodge, T.T. Kawabata, S. Krishnaswami, J.D. Clark, J.B. Telliez, M.E. Dowty, S. Menon, M. Lamba, S. Zwillich, The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis, Clin. Exp. Rheumatol. 34 (2) (2016) 318–328.
- [7] R. Fleischmann, A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate, Expet Opin. Pharmacother. 18 (14) (2017) 1525–1533.
- [8] J.D. Clark, M.E. Flanagan, J.B. Telliez, Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases, J. Med. Chem. 57 (12) (2014) 5023–5038.
- [9] R. The Lancet, JAK inhibitors: fate in doubt for rheumatoid arthritis? The Lancet Rheumatology 3 (3) (2021) e161.
- [10] J.J. O'Shea, M. Gadina, Selective Janus kinase inhibitors come of age, Nat. Rev. Rheumatol. 15 (2) (2019) 74–75.
- [11] Y. Tanaka, Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside, J. Biochem. 158 (3) (2015) 173–179.
- [12] J. Peiró Cadahía, V. Previtali, N.S. Troelsen, M.H. Clausen, Prodrug strategies for targeted therapy triggered by reactive oxygen species, Med. Chem. Commun. 10 (9) (2019) 1531–1549.
- [13] H. Maslah, C. Skarbek, S. Pethe, R. Labruère, Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment, Eur. J. Med. Chem. 207 (2020) 112670.
- [14] P. Wang, Q. Gong, J. Hu, X. Li, X. Zhang, Reactive oxygen species (ROS)-Responsive prodrugs, probes, and theranostic prodrugs: applications in the ROS-related diseases, J. Med. Chem. 64 (1) (2021) 298–325.
- [15] K. Matsushita, T. Okuda, S. Mori, M. Konno, H. Eguchi, A. Asai, J. Koseki, Y. Iwagami, D. Yamada, H. Akita, T. Asaoka, T. Noda, K. Kawamoto, K. Gotoh,

S. Kobayashi, Y. Kasahara, K. Morihiro, T. Satoh, Y. Doki, M. Mori, H. Ishii, S. Obika, A hydrogen peroxide activatable gemcitabine prodrug for the selective treatment of pancreatic ductal adenocarcinoma, ChemMedChem 14 (15) (2019) 1384–1391.

- [16] M. Lu, X. Zhang, J. Zhao, Q. You, Z. Jiang, A hydrogen peroxide responsive prodrug of Keap1-Nrf2 inhibitor for improving oral absorption and selective activation in inflammatory conditions, Redox Biol 34 (2020) 101565.
- [17] J.E. Palmer, B.M. Brietske, T.C. Bate, E.A. Blackwood, M. Garg, C.C. Glembotski, C.B. Cooley, Reactive oxygen species (ROS)-Activatable prodrug for selective activation of ATF6 after ischemia/reperfusion injury, ACS Med. Chem. Lett. 11 (3) (2020) 292–297.
- [18] Q. Bao, L. Zhang, N. Wang, B. Gabet, W. Yang, X. Gao, Q. You, Z. Jiang, Hydrogen peroxide inducible JAK3 covalent inhibitor: prodrug for the treatment of RA with enhanced safety profile, ACS Med. Chem. Lett. 11 (11) (2020) 2182–2189.
- [19] X. Wei, J. Wu, G. Zhao, J. Galdamez, S.M. Lele, X. Wang, Y. Liu, D.M. Soni, P.E. Purdue, T.R. Mikuls, S.R. Goldring, D. Wang, Development of a Janus kinase inhibitor prodrug for the treatment of rheumatoid arthritis, Mol. Pharm. 15 (8) (2018) 3456–3467.
- [20] J. Peiró Cadahía, J. Bondebjerg, C.A. Hansen, V. Previtali, A.E. Hansen, T.L. Andresen, M.H. Clausen, Synthesis and evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis, J. Med. Chem. 61 (8) (2018) 3503–3515.
- [21] N.S. Andersen, J. Peiró Cadahía, V. Previtali, J. Bondebjerg, C.A. Hansen, A.E. Hansen, T.L. Andresen, M.H. Clausen, Methotrexate prodrugs sensitive to reactive oxygen species for the improved treatment of rheumatoid arthritis, Eur. J. Med. Chem. 156 (2018) 738–746.
- [22] A. Daina, O. Michielin, V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep. 7 (1) (2017) 42717.
- [23] P.S. Changelian, M.E. Flanagan, D.J. Ball, C.R. Kent, K.S. Magnuson, W.H. Martin, B.J. Rizzuti, P.S. Sawyer, B.D. Perry, W.H. Brissette, S.P. McCurdy, E.M. Kudlacz, M.J. Conklyn, E.A. Elliott, E.R. Koslov, M.B. Fisher, T.J. Strelevitz, K. Yoon, D.A. Whipple, J. Sun, M.J. Munchhof, J.L. Doty, J.M. Casavant, T.A. Blumenkopf, M. Hines, M.F. Brown, B.M. Lillie, C. Subramanyam, C. Shang-Poa, A.J. Milici, G.E. Beckius, J.D. Moyer, C. Su, T.G. Woodworth, A.S. Gaweco, C.R. Beals, B.H. Littman, D.A. Fisher, J.F. Smith, P. Zagouras, H.A. Magna, M.J. Saltarelli, K.S. Johnson, L.F. Nelms, S.G. Des Etages, L.S. Hayes, T.T. Kawabata, D. Finco-Kent, D.L. Baker, M. Larson, M.S. Si, R. Paniagua, J. Higgins, B. Holm, B. Reitz, Y.J. Zhou, R.E. Morris, J.J. O'Shea, D.C. Borie, Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor, Science 302 (5646) (2003) 875–878.
- [24] J.-k. Jiang, K. Ghoreschi, F. Deflorian, Z. Chen, M. Perreira, M. Pesu, J. Smith, D.-T. Nguyen, E.H. Liu, W. Leister, S. Costanzi, J.J. O'Shea, C.J. Thomas, Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3oxopropanenitrile (CP-690.550), J. Med. Chem. 51 (24) (2008) 8012–8018.
- [25] M.E. Dowty, M.I. Jesson, S. Ghosh, J. Lee, D.M. Meyer, S. Krishnaswami, N. Kishore, Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis, J. Pharmacol. Exp. Therapeut. 348 (1) (2014) 165–173.
- [26] A. Dixit, S.R. Mallurwar, S.P. Sulochana, M. Zainuddin, R. Mullangi, Determination of tofacitinib in mice whole blood on dried blood spots using LC-ESI-MS/MS: application to pharmacokinetic study in mice, Drug Res. 69 (6) (2019) 330–336.
- [27] J.S. Lee, H.S. Kim, Y.S. Jung, H.G. Choi, S.H. Kim, Pharmacokinetic drug interaction between tofacitinib and voriconazole in rats, Pharmaceutics 13 (5) (2021).
- [28] V. Previtali, K. Petrovic, J. Peiró Cadahía, N.S. Troelsen, M.H. Clausen, Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis, Bioorg. Med. Chem. Lett 28 (2) (2020) 115247.
- [29] G. Latacz, A. Lubelska, M. Jastrzębska-Więsek, A. Partyka, A. Sobito, A. Olejarz, K. Kucwaj-Brysz, G. Satała, A.J. Bojarski, A. Wesołowska, K. Kieć-Kononowicz, J. Handzlik, In the search for a lead structure among series of potent and selective hydantoin 5-HT7R agents: the drug-likeness in vitro study, Chem. Biol. Drug Des. 90 (6) (2017) 1295–1306.
- [30] Corning® BioCoat<sup>TM</sup> Pre-coated PAMPA Plate System.
- [31] L.K. Sørensen, N.F. Rittig, E.F. Holmquist, K.A. Jørgensen, J.O.L. Jørgensen, N. Møller, M. Johannsen, Simultaneous determination of β-hydroxybutyrate and β-hydroxy-β-methylbutyrate in human whole blood using hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry, Clin. Biochem. 46 (18) (2013) 1877–1883.